Your browser doesn't support javascript.
Systems serology detects functionally distinct coronavirus antibody features in children and elderly.
Selva, Kevin J; van de Sandt, Carolien E; Lemke, Melissa M; Lee, Christina Y; Shoffner, Suzanne K; Chua, Brendon Y; Davis, Samantha K; Nguyen, Thi H O; Rowntree, Louise C; Hensen, Luca; Koutsakos, Marios; Wong, Chinn Yi; Mordant, Francesca; Jackson, David C; Flanagan, Katie L; Crowe, Jane; Tosif, Shidan; Neeland, Melanie R; Sutton, Philip; Licciardi, Paul V; Crawford, Nigel W; Cheng, Allen C; Doolan, Denise L; Amanat, Fatima; Krammer, Florian; Chappell, Keith; Modhiran, Naphak; Watterson, Daniel; Young, Paul; Lee, Wen Shi; Wines, Bruce D; Mark Hogarth, P; Esterbauer, Robyn; Kelly, Hannah G; Tan, Hyon-Xhi; Juno, Jennifer A; Wheatley, Adam K; Kent, Stephen J; Arnold, Kelly B; Kedzierska, Katherine; Chung, Amy W.
  • Selva KJ; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • van de Sandt CE; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Lemke MM; Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Lee CY; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
  • Shoffner SK; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
  • Chua BY; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
  • Davis SK; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Nguyen THO; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Rowntree LC; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Hensen L; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Koutsakos M; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Wong CY; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Mordant F; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Jackson DC; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Flanagan KL; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC, Australia.
  • Crowe J; Department of Infectious Diseases and Tasmanian Vaccine Trial Centre, Launceston General Hospital, Launceston, TAS, Australia.
  • Tosif S; School of Health Sciences and School of Medicine, University of Tasmania, Launceston, TAS, Australia.
  • Neeland MR; Department of Immunology and Pathology, Monash University, Melbourne, VIC, Australia.
  • Sutton P; School of Health and Biomedical Science, RMIT University, Melbourne, VIC, Australia.
  • Licciardi PV; Deepdene Surgery, Deepdene, VIC, Australia.
  • Crawford NW; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Cheng AC; Department of General Medicine, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia.
  • Doolan DL; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia.
  • Amanat F; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Krammer F; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia.
  • Chappell K; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Modhiran N; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia.
  • Watterson D; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Young P; Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia.
  • Lee WS; Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Wines BD; Immunisation Service, Royal Children's Hospital Melbourne, Melbourne, VIC, Australia.
  • Mark Hogarth P; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Esterbauer R; Infection Prevention & Healthcare Epidemiology Unit, Alfred Health, Melbourne, VIC, Australia.
  • Kelly HG; Centre for Molecular Therapeutics, Australian Institute of Tropical Health & Medicine, James Cook University, Cairns, QLD, Australia.
  • Tan HX; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Juno JA; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Wheatley AK; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kent SJ; School of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.
  • Arnold KB; School of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.
  • Kedzierska K; School of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.
  • Chung AW; School of Chemistry and Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia.
Nat Commun ; 12(1): 2037, 2021 04 01.
Article in English | MEDLINE | ID: covidwho-1164849
ABSTRACT
The hallmarks of COVID-19 are higher pathogenicity and mortality in the elderly compared to children. Examining baseline SARS-CoV-2 cross-reactive immunological responses, induced by circulating human coronaviruses (hCoVs), is needed to understand such divergent clinical outcomes. Here we show analysis of coronavirus antibody responses of pre-pandemic healthy children (n = 89), adults (n = 98), elderly (n = 57), and COVID-19 patients (n = 50) by systems serology. Moderate levels of cross-reactive, but non-neutralizing, SARS-CoV-2 antibodies are detected in pre-pandemic healthy individuals. SARS-CoV-2 antigen-specific Fcγ receptor binding accurately distinguishes COVID-19 patients from healthy individuals, suggesting that SARS-CoV-2 infection induces qualitative changes to antibody Fc, enhancing Fcγ receptor engagement. Higher cross-reactive SARS-CoV-2 IgA and IgG are observed in healthy elderly, while healthy children display elevated SARS-CoV-2 IgM, suggesting that children have fewer hCoV exposures, resulting in less-experienced but more polyreactive humoral immunity. Age-dependent analysis of COVID-19 patients, confirms elevated class-switched antibodies in elderly, while children have stronger Fc responses which we demonstrate are functionally different. These insights will inform COVID-19 vaccination strategies, improved serological diagnostics and therapeutics.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / Antibodies, Viral / Antibody Formation Type of study: Prognostic study / Qualitative research / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Aged / Child / Child, preschool / Humans / Middle aged / Young adult Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-22236-7

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / Antibodies, Viral / Antibody Formation Type of study: Prognostic study / Qualitative research / Randomized controlled trials Topics: Vaccines Limits: Adolescent / Adult / Aged / Child / Child, preschool / Humans / Middle aged / Young adult Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-22236-7